Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2′- deoxyribose

Clinical Cancer Research

Volumn 10, Issue 22, 2004, Pages 7520-7528

  Seo, Yuji ^a   Yan, Tao ^a   Schupp, Jane E ^a   Colussi, Valdir ^a   Taylor, Kerri L ^a   Kinsella, Timothy J ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 IODO 2 PYRIMIDINONE 2' DEOXYRIBOSE; CELL DNA; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; MISMATCH REPAIR; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOSENSITIZATION; TUMOR XENOGRAFT;

ANIMALS; BASE PAIR MISMATCH; CELL CYCLE; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA; DNA REPAIR; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; PYRIMIDINE NUCLEOSIDES; RADIATION-SENSITIZING AGENTS; TIME FACTORS;

EID: 9344235474     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1144     Document Type: Article

References (46)

1. Kinsella TJ, Kunugi KA, Vielhuber KA, et al. An in vivo comparison of oral 5-iodo-2′-deoxyuridine and 5-iodo-2-pyrimidinone-2′-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116. Cancer Res 1994;54:2695-700.
2. Kinsella TJ. An approach to the radiosensitization of human tumors. Cancer J Sci Am 1996;2:184.
3. Kinsella TJ, Kunugi KA, Vielhuber KA, et al. Preclinical evaluation of 5-iodo-2-pyrimidinone-2′-deoxyribose as a prodrug for 5-iodo-2′- deoxyuridine-mediated radiosensitization in mouse and human tissues. Clin Cancer Res 1998;4:99-109.
4. Kinsella TJ, Vielhuber KA, Kunugi KA, et al. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2′- deoxyribose as a prodrug for 5-iodo-2′-deoxyuridine radiosensitization in U251 human glioblastoma xenografts. Clin Cancer Res 2000;6:1468-75.
5. Kinsella TJ, Schupp JE, Davis TW, et al. Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2′- deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study design. Clin Cancer Res 2000;6:3670-9.
6. Chang CN, Doong SL, Cheng YC, Conversion of 5-iodo-2-pyrimidinone- 2′-deoxyribose to 5-iodo-deoxyuridine by aldehyde oxidase. Implication in hepatotropic drug design. Biochem Pharmacol 1992;43:2269-73.
7. Kinsella TJ, Mitchell JB, Russo A, Morstyn G, Glatstein E. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers. Int J Radiat Oncol Biol Phys 1984;10:1399-406.
8. Kinsella TJ, Collins J, Rowland J, et al. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J Clin Oncol 1988;6:871-9.
9. Chang AE, Collins JM, Speth PA, et al. A phase I study of intraarterial iododeoxyuridine in patients with colorectal liver metastases. J Clin Oncol 1989;7:662-8.
10. Goffman T, Tochner Z, Glatstein E. Primary treatment of large and massive adult sarcomas with iododeoxyuridine and aggressive hyperfractionated irradiation. Cancer (Phila.) 1991;67:572-6.
11. Urtasun RC, Cosmatos D, DelRowe J, et al. Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: a comparison of short versus long intravenous dose schedules (RTOG 86-12). Int J Radiat Oncol Biol Phys 1993;27:207-14.
12. Epstein AH, Lebovics RS, Goffman T, et al. Treatment of locally advanced cancer of the head and neck with 5′-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement. J Natl Cancer Inst (Bethesda) 1994;86:1775-80.
13. Epstein AH, Lebovics RS, Van Waes C, et al. Intravenous delivery of 5′-iododeoxyuridine during hyperfractionated radiotherapy for locally advanced head and neck cancers: results of a pilot study. Laryngoscope 1998;108:1090-4.
14. Sondak VK, Robertson JM, Sussman JJ, et al. Preoperative idoxuridine and radiation for large soft tissue sarcomas: clinical results with five-year follow-up. Ann Surg Oncol 1998;5:106-12.
15. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003;21:1174-9.
16. Lage H, Dietel M, Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol 1999;125:156-65.
17. Bignami M, Casorelli I, Karran P. Mismatch repair and response to DNA-damaging antitumour therapies. Eur J Cancer 2003;39:2142-9.
18. Kat A, Thilly WG, Fang WH, et al. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 1993;90:6424-8.
19. Friedman HS, Johnson SP, Dong Q, et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 1997;57:2933-6.
20. Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science (Wash DC) 1996;273:1109-11.
21. Meyers M, Hwang A, Wagner MW, et al. A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. Oncogene 2003;22:7376-88.
22. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.
23. Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and Adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996;271:19645-8.
24. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-6.
25. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996;56:3087-90.
26. Davis TW, Wilson-Van Patten C, Meyers M, et al. Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res 1998;58:767-78.
27. Yan T, Schupp JE, Hwang HS, et al. Loss of DNA mismatch repair imparts defective cdc2 signaling and G arrest responses without altering survival after ionizing radiation. Cancer Res 2001;61:8290-7.
28. Fritzell JA, Narayanan L, Baker SM, et al. Role of DNA mismatch repair in the cytotoxicity of ionizing radiation. Cancer Res 1997;57:5143-7.
29. Franchitto A, Pichierri P, Piergentili R, et al. The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase. Oncogene 2003;22:2110-20.
30. DeWeese TL, Shipman JM, Larrier NA, et al. Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation. Proc Natl Acad Sci USA 1998;95:11915-20.
31. Zeng M, Narayanan L, Xu XS, et al. Ionizing radiation-induced apoptosis via separate Pms2- and p53-dependent pathways. Cancer Res 2000;60:4889-93.
32. Berry SE, Garces C, Hwang HS, et al. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells. Cancer Res 1999;59:1840-5.
33. Berry SE, Davis TW, Schupp JE, et al. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine. Cancer Res 2000;60:5773-80.
34. Berry SE, Kinsella TJ. Targeting DNA mismatch repair for radiosensitization. Semin Radiat Oncol 2001;11:300-15.
35. Berry SE, Loh T, Yan T, Kinsella TJ. Role of MutSalpha in the recognition of iododeoxyuridine in DNA. Cancer Res 2003;63:5490-5.
36. Fornace AJ Jr, Dobson PP, Kinsella TJ. Enhancement of radiation damage in cellular DNA following unifilar substitution with iododeoxyuridine. Int J Radiat Oncol Biol Phys 1990;18:873-8.
37. Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD. The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells. Radiat Res 1990;123:192-8.
38. Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure. Int J Radiat Oncol Biol Phys 1990;18:1393-8.
39. Miller EM, Fowler JF, Kinsella TJ, Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. I. Radiosensitization of human colon cancer cells by iododeoxyuridine Radiat Res 1992;131:81-9.
40. Belanger K, Collins JM, Klecker RW Jr. Technique for detection of DNA nucleobases by reversed-phase high-performance liquid chromatography optimized for quantitative determination of thymidine substitution by iododeoxyuridine. J Chromatogr 1987;417:57-63.
41. Rodriguez R, Ritter MA, Fowler JF, Kinsella TJ. Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo. Int J Radiat Oncol Biol Phys 1994;29:105-13.
42. Eisbruch A, Robertson JM, Johnston CM, et al. Bromodeoxyuridine alternating with radiation for advanced uterine cervix cancer: a phase 1 and drug incorporation study. J Clin Oncol 1999;17:31-40.
43. Hawn MT, Umar A, Carethers JM, et al. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res 1995;55:3721-5.
44. Brown R, Hirst GL, Gallagher WM, et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997;15:45-52.
45. Taverna P, Hwang HS, Schupp JE, et al. Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization. Cancer Res 2003;63:838-46.
46. Cortellino S, Turner D, Masciullo V, et al. The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci USA 2003;100:15071-6.